Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 84 for your search:
Cancer Type/Condition:
Oropharyngeal cancer
Stage/Subtype:
stage III oropharyngeal cancer
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Induction Chemotherapy Comprising Docetaxel, Cisplatin, and Fluorouracil Followed By Radiotherapy and Carboplatin or Docetaxel Versus Radiotherapy and Cisplatin Only in Patients With Previously Untreated Stage III or IV Squamous Cell Carcinoma of the Head and Neck (Paradigm Trial)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
DFCI-04006
, AVENTIS-DFCI-04006, NCT00095875, PARADIGM TRIAL
2.
Phase III of Unilateral Neck Irradiation With Amifostine in Patients With SCC of the Head and Neck
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
186-03
, ETH136-03D, NCT00206752
3.
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EGF102988
, NCT00424255
4.
Phase III Randomized Study of Radiotherapy and Cisplatin With Versus Without Fluorouracil in Patients With Stage III or IV Squamous Cell Head and Neck Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CASE-3307-CC389
, CASE-3307, CASE-CC389, CASE3307-CC389, NCT00608205
5.
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
Hx-EGFr-203
, NCT00401401
6.
Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
UCIRB #14735B
, GV-001.010 (TNF-ELF), NCT00496236
7.
A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
UCIRB #14733B
, GV-001.011 (TNF-CORE), NCT00496535
8.
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
07-069
, NCT00570674
9.
Phase I/II Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
MCC-15461
, IND 102483, LBH589, NCT00738751
10.
Phase I/II Study of Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Cisplatin, Cetuximab, and Radiotherapy in Patients With Local-Regionally Advanced Squamous Cell Carcinoma of the Head and Neck
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
SCCC-112008-019
, 112008-019, ABX 236-HN08US, NCT00851877
11.
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CR015580
, NCT00841191
12.
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in NNSCC
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 90
Sponsor:
Other
Protocol IDs:
J08101
, CA180123, NCT00882583
13.
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Phase:
Phase II, Phase I
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
603EUSA03
, NCT00901732
14.
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GCO # 06-0509
, NCT00970502
15.
A Study of RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic Squamous Cell Cancer of the Head and Neck
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
J0916
, NA_00023951, NCT01009346
16.
Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
OSU-0482
, NCT00293579
17.
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
OSI-3601S
, Genentech, Inc., NCT00304278
18.
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
H-26154 (GCC 0442)
, CA225092, NCT00343083
19.
Use of Cone Beam Kilovaltage Imaging in Patients Receiving Radiation Therapy for Head and Neck Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
06U.195
, NCT00358007
20.
Phase II Study of Chemoradiotherapy Comprising Cisplatin, Bevacizumab, and Intensity-Modulated Radiotherapy in Patients With Stage III or IV Squamous Cell Carcinoma of the Head and Neck
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
MSKCC-06130
, PFIZER-MSKCC-06130, NCT00423930
21.
Phase II Randomized Study of Cisplatin and Radiotherapy With or Without Erlotinib Hydrochloride in Patients With Stage III or IV Squamous Cell Carcinoma of the Head and Neck
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UWCC-6106
, 6106, UWCC-05-9278-H/B, GENENTECH-OSI3602s, FHCRC-6106, NCT00410826
22.
Fluorouracil, Hydroxyurea, Cetuximab and Twice-Daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GCO 06-1155
, NCT00462735
23.
Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
14401A
, NCT00468169
24.
Phase II Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
ENT0020
, 97864, ENT0020, LAP #109855, NCT00490061, NCT00490061
25.
Sorafenib Plus Carboplatin and Paclitaxel in Head and Neck Squamous Cell Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2006-0940
, NCT00494182
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
